Building A Healthier Future

Serving the Globe with Affordable and High-quality Therapies.

RPG Life Sciences is an integrated pharmaceutical company with manufacturing infrastructure, experience, skillset, and strong front-end and backend capabilities operating in the domestic and international markets in Branded Formulations, Global Generics and APIs.

RPG Life Sciences manufactures and markets a range of high-value niche APIs for global markets. The company has a diverse product portfolio spanning 13 therapy areas. Its product portfolio includes some well-known textbook brands such as Aldactone, Serenace, Naprosyn, and Azoran. The company has products that treat both acute as well as chronic illnesses. Its brands are highly trusted by healthcare professionals and patients worldwide.

RPG Life Sciences is a forward-looking pharmaceutical organisation poised for high-trajectory growth. With eyes firmly set on the future, RPG Life Sciences is equipped to explore opportunities in the marketplace to achieve stakeholder delight.

VISIT WEBSITE

"We wish to be a benchmark company focused on our strategic priorities

to achieve sustainable profitable growth while living our cherished value of patient centricity."

Yugal Sikri

Managing Director, RPG Life Sciences

“RPG Life Sciences is on a virtuous cycle of serving existing

opportunities distinctively and adding adjacent ones along the way”

Rajat Bhargava

President & CEO, Speciality Sector

Latest Stories

Yugal Sikri, MD, RPG Life Sciences speaks to CNBC-TV18

Yugal Sikri, MD, RPG Life Sciences speaks to CNBC-TV18 on business outlook

RPG Life Sciences के Q4 Results, Growth & Business Model पर MD Yugal Sikri का Outlook

Yugal Sikri, MD, RPG Life Sciences speaks to ET Now Swadesh on Q4FY23

Wockhardt, RPG Life Sciences MDs bat for innovation to drive growth in pharma industry

Yugal Sikri, MD, RPG Life Sciences speaks to ET Now Swadesh on Q3FY23 performance

Panel Discussion: The COVID-19 impact on packaging

Yugal Sikri, MD, RPG Life Sciences on H2FY23 outlook

Yugal Sikri, MD, RPG Life Sciences speaks to ET NOw on the company's Q2 FY23 performance